Katul

Drospirenone and ethinylestradiol, the active ingredients in Katul, are a combined oral contraceptive presented as an oral tablet for oral use. The product belongs to the drug class of combined oral contraceptives and is prescribed for women of reproductive age to prevent pregnancy by suppressing ovulation.

GNH USA supplies Katul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourcing the product from EU‑authorized manufacturers and adhering to stringent quality standards. The company provides regulatory documentation and supports import logistics for global distribution.

Katul, a combined oral contraceptive, is used to prevent pregnancy by acting on the hormonal regulation of the menstrual cycle.

Contraception: provides reliable prevention of pregnancy in women of reproductive age. Family planning: enables planned spacing of pregnancies for women seeking to control childbearing. Menstrual cycle regulation: helps achieve more predictable menstrual periods and may reduce cycle‑related symptoms. Acne management: may improve mild acne associated with hormonal fluctuations.

Katul may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial pain. - Breast tenderness: discomfort or swelling of the breasts. - Spotting: irregular vaginal bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Stroke: cerebrovascular accident, especially in high‑risk individuals. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Katul, clinicians should evaluate individual risk factors and contraindications. - Contraindication: do not use in women with known thromboembolic disorders or estrogen‑dependent tumors. - Smoking: avoid if over 35 years and a smoker, as risk of cardiovascular events increases. - Medication review: assess concomitant use of enzyme‑inducing drugs that may reduce efficacy. - Blood pressure monitoring: check regularly, especially in patients with hypertension. - Pregnancy: contraindicated; discontinue immediately if pregnancy occurs. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Katul can interact with several medicines, altering its effectiveness or increasing side‑effect risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce hormone levels, compromising contraceptive effect. - Selective serotonin reuptake inhibitors (e.g., fluoxetine) at high doses: may increase risk of hormonal side effects. - Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., tetracycline): may slightly decrease effectiveness; advise backup contraception. - Herbal supplements (e.g., St John’s wort): may lower plasma levels of hormones. - Diuretics (e.g., spironolactone): may enhance anti‑mineralocorticoid effect, leading to electrolyte changes.